TORONTO and EDMONTON, Alberta, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to ...
Aeterna Zentaris Presents Positive Final Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ESGO Meeting in Milan, Italy QUÉBEC CITY, Sept. 14, 2011 /PRNewswire via COMTEX ...
Data Reported at ASCO Confirm a Statistically Significant Improvement in Both Time to Tumor Progression and Overall Survival in the Perifosine + Capecitabine Arm ...
The parties anticipate completing the Transaction in the second quarter of 2024, subject to obtaining all required approvals and satisfying all required conditions. Further disclosure on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback